Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Plc Regulatory News (ZTF)

Share Price Information for Zotefoams Plc (ZTF)

Share Price is delayed by 15 minutes
Get Live Data
424.00    -15.00 (-3.42%)
Bid:
426.00
Ask:
430.00
Spread: 4.00 (0.939%)
Market Cap: £208.53m
ZTF Live PriceLast checked at - London Stock Exchange

Intraday Zotefoams Plc Share Chart

Interim Management Statement

26 Oct 2012 07:00

RNS Number : 5898P
Zotefoams PLC
26 October 2012
 



26 October 2012

 

Zotefoams plc

("Zotefoams" or "the Company")

 

Interim Management Statement for the Quarter ended 30 September 2012

 

26 October 2012 - Zotefoams, which manufactures and sells high-performance foams, today announces its interim management statement for the third quarter ended 30 September 2012.

 

Third quarter Polyolefin foam sales increased by approximately 3% in constant currency compared to the same period last year. Sales growth in North America and Rest of World was around 6% while we experienced more modest growth in UK and Continental Europe. The impact of a weaker euro reduced the sterling value of European sales by approximately 10% while there was a small positive impact on sales elsewhere from relative US dollar strength compared with the third quarter in 2011.

 

In the third quarter of 2011 there was high demand for our T-Tubes® insulation products and, due to timing of projects, comparative sales were much lower in 2012. As a result, revenue from our High-Performance Polymers ("HPP") segment was approximately 20% below the same period last year despite an increase in sales of our patented ZOTEK® F fluoropolymer foams. While sales in HPP have historically been subject to short term fluctuations, we remain confident of strong underlying growth in this segment, much of which is to the aviation market.

 

In July and August 2012 MuCell Extrusion LLC ("MEL"), which licenses foaming technology, made important advances within the film and sheet markets. Agreements with Dow Chemical and Styron to license-in their complementary patents have enhanced our ability to offer attractive licences in packaging technology, and activity and interest levels have increased as a direct result. The development pipeline of new projects continues to grow from a small base and in the medium term we expect good progress in conversion of additional signed MEL licences. Currently MEL is a developmental business which is cash generative and we are increasing investment commensurate with our expectations for growth over the coming years.

 

For the third quarter the euro-denominated price of low density polyethylene (LDPE), our main raw material, was at a similar average price compared to the same period last year.

 

The Company continues to progress, with a forward order book into early 2013. Although we are mindful of the uncertain economic environment and the potential for movements in exchange rates to have a translation impact on our reported results, the Board remains confident of a satisfactory outcome for the year and continued progress in the future.

 

 

Enquiries:

Zotefoams plc

0208-664-1600

David Stirling, Managing Director

Clifford Hurst, Finance Director

FTI Consulting

0207-831-3113

Ben Brewerton, John Dineen, Victoria Foster Mitchell

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular material technology. Using a unique manufacturing process with environmentally friendly nitrogen expansion, Zotefoams produces lightweight foams in Croydon, UK and Kentucky, USA for diverse markets worldwide through its global sales force. Zotefoams also owns and licenses patented MuCell® microcellular foam technology from a base in Massachusetts, USA to customers worldwide and sells T-Tubes® advanced insulation systems made from its patented ZOTEK® fluoropolymer foams.

 

www.zotefoams.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVSBRUSARUAA
Date   Source Headline
27th May 20264:06 pmRNSNotification of Transactions of Directors/PDMRs
27th May 20264:00 pmRNSResult of the 2026 Annual General Meeting
27th May 20267:00 amRNSTrading Update
12th May 20267:00 amRNSInvestor Presentation via Investor Meet Company
11th May 20267:00 amRNSNotification of Transactions of Directors/PDMRs
7th May 20267:00 amRNSIssue of Equity
30th Apr 20261:00 pmRNSFinal Dividend Payment Date
27th Apr 20267:00 amRNS2025 Annual Report and Notice of the 2026 AGM
15th Apr 20269:24 amRNSNotification of Transactions of Directors/PDMRs
31st Mar 20266:06 pmRNSHolding(s) in Company
25th Mar 20269:35 amRNSNotification Of Transactions Of Directors/PDMRs
17th Mar 20267:00 amRNSPreliminary Results
17th Mar 20267:00 amRNSPreliminary Results
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
16th Mar 20261:24 pmRNSNotification Of Transactions Of Directors/PDMRs
11th Mar 20267:00 amRNSPreliminary results presentation
11th Mar 20267:00 amRNSPreliminary results presentation
13th Feb 20267:00 amRNSNotification Of Transactions Of Directors/PDMRs
27th Jan 20267:00 amRNSChange of Registered Office Address
22nd Jan 20267:00 amRNSTrading Update
15th Jan 20269:57 amRNSNotification Of Transactions Of Directors/PDMRs
15th Dec 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
18th Nov 202512:39 pmRNSAcquisition of Overseas Konstellation Company S.A.
12th Nov 20254:12 pmRNSNotification Of Transactions Of Directors/PDMRs
4th Nov 20257:00 amRNSTrading Update
24th Oct 20257:00 amRNSNon-Executive Directorate Changes
14th Oct 20252:54 pmRNSNotification Of Transactions Of Directors/PDMRs
9th Oct 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Sep 20254:25 pmRNSNOTIFICATION OF TRANSACTIONS OF DIRECTORS/PDMRs
22nd Sep 20252:33 pmRNSGroup CFO succession
12th Sep 20255:11 pmRNSNotification Of Transactions Of Directors/PDMR
28th Aug 20257:00 amRNS-RInnovation Initiatives and Executive Appointment
19th Aug 20252:16 pmRNSHolding(s) in Company
14th Aug 20256:19 pmRNSHolding(s) in Company
12th Aug 20252:57 pmRNSNotification Of Transactions Of Directors/PDMR
8th Aug 20257:00 amRNSHolding(s) in Company
7th Aug 202512:14 pmRNSHolding(s) in Company
5th Aug 20257:01 amRNSJoint Venture Agreement and Executive Appointment
5th Aug 20257:00 amRNSInterim Results
29th Jul 202511:01 amRNSInvestor Presentation via Investor Meet Company
14th Jul 20252:51 pmRNSNotification Of Transactions Of Directors/PDMRs
12th Jun 20252:41 pmRNSNotification of Transactions of Directors/PDMRs
10th Jun 20254:13 pmRNSNotification Of Transactions Of Directors/PDMRs
22nd May 202512:30 pmRNSResult of the 2025 Annual General Meeting
22nd May 20257:00 amRNSTrading Update
13th May 202512:05 pmRNSNotification Of Transactions Of Directors/PDMRs
1st May 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
30th Apr 20257:00 amRNSGroup CFO succession
24th Apr 20257:00 amRNSNotification Of Transactions Of Directors/PDMRs
22nd Apr 20257:00 amRNS2024 Annual Report & Notice of 2025 AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.